Valuation: OpGen Inc

Market Cap 198M 174M 160M 148M 280M 18.9B 285M 1.91B 750M 9.31B 744M 728M 32.03B P/E 2024
0.26x
P/E 2025 6.86x
Enterprise Value 199M 175M 161M 149M 282M 19.02B 287M 1.92B 755M 9.37B 749M 733M 32.25B EV / Sales 2024
1.29x
EV / Sales 2025 5.39x
Free-Float
-
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Executive Officer 50 30/11/2025
Chief Tech/Sci/R&D Officer 37 31/03/2025
Chief Operating Officer 54 03/12/2024
Director TitleAgeSince
Chairman 36 01/08/2024
Director/Board Member 39 08/08/2024
Director/Board Member 40 08/08/2024
Change 5-day change 1-year change 3-year change Capi.($)
+21.45%+1,817.73% - - 6.39M
+0.58%+2.06%+2.92%+10.86% 50.73B
-2.22%-1.25%+385.40%+586.81% 39.73B
-0.54%+0.39%+25.57%-5.28% 34.69B
-1.36%+0.35%+17.88%+55.14% 33.21B
+1.21%-4.58%+3.00%+35.46% 26.76B
-1.81%-1.48% - - 16.8B
+0.51%-3.47%+63.97%+122.60% 15.37B
+0.23%-0.58%+13.76%+21.11% 13.78B
-0.62%-3.09%+10.29%-31.35% 12.85B
Average +1.74%-0.83%+65.35%+99.42% 27.1B
Weighted average by Cap. -0.48%-0.23%+80.69%+124.32%

Financials

2024 2025
Net sales 5.2M 4.55M 4.2M 3.88M 7.35M 496M 7.48M 50.14M 19.67M 244M 19.51M 19.08M 840M 30.2M 26.46M 24.4M 22.54M 42.74M 2.88B 43.45M 291M 114M 1.42B 113M 111M 4.88B
Net income 11.99M 10.51M 9.69M 8.95M 16.97M 1.14B 17.26M 116M 45.39M 563M 45.02M 44.05M 1.94B 23.62M 20.69M 19.08M 17.63M 33.43M 2.25B 33.99M 228M 89.4M 1.11B 88.68M 86.75M 3.82B
Net Debt 711K 623K 574K 531K 1.01M 67.8M 1.02M 6.86M 2.69M 33.4M 2.67M 2.61M 115M 1.32M 1.15M 1.06M 983K 1.86M 126M 1.89M 12.71M 4.98M 61.85M 4.94M 4.84M 213M
Logo OpGen Inc
OpGen, Inc. (OpGen) is a precision medicine company using molecular diagnostics and informatics to combat infectious disease. The Company is engaged in developing molecular information solutions to combat infectious disease in global healthcare settings, helping to guide clinicians with information about life threatening infections, managing patient outcomes, and the spread of infections caused by multidrug-resistant microorganisms. Its deoxyribonucleic acid (DNA) tests and bioinformatics address the threat of anti-biotic resistance by helping physicians and healthcare providers manage patient care decisions and protect the hospital biome through customized screening and surveillance solutions. It is working to deliver its molecular information solution to a global network of customers and partners. It is also working to provide precise diagnostic information powered by pathogen surveillance data. The Company's high-resolution DNA tests are marketed under the Acuitas trade name.
Employees
-